CSMG Technologies Announces Live Tissue Connect Subsidiary Successfully Uses Tissue Bonding in Pediatric Procedures.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc. (OTCBB: CTUM), a technology management company focused on commercializing human live tissue bonding devices, announced 170 human pediatric surgeries have been performed on patients, from ages six months to 17 years, using the company's platform live biological tissue welding/bonding technology. The surgeries were performed at the Zhytomir Children's Hospital, Zhytomir, Ukraine.

Dr. Vitaliy Zaremba, researcher and surgeon at the Zhytomir Children's Hospital said, "The technology is being used in various types of pediatric surgeries, including circumcision, tissue separation, tissue reconnection, gynecology, thoracic surgery, tumor removal, ovarian and urological procedures. The main advantages over conventional surgery procedures are absence of bleeding, safety of the surgery, less procedure time and faster patient recovery."

Donald S. Robbins, president and CEO of CSMG, said, "It is rewarding to note the consistent remarks by surgeons of the advantages our tissue welding technology produces, especially when considering the wide range of procedures we are able to perform, versus conventional wound closing methods. Particularly impressive is the ability to successfully apply the technology to small pediatric organs and tedious procedures. We are continually expanding our procedure capabilities, thus increasing our licensing and marketing opportunities."

CSMG owns the technology and exclusive world rights to the medical device through Live Tissue Connect, Inc. (LTC), a subsidiary corporation formed for the development and exploitation of the platform technology.

LTC expects to complete a U.S. and European regulatory device for duct and vessel sealing meeting FDA and European CE Mark standards, respectively, and file for approval of the device with the two regulatory entities early next year.

About CSMG Technologies' Tissue Welding/Bonding Technology

The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matters, or conventional wound closing devices, such as sutures, staples, sealant, or glues. Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 7,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter.

Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.